Melanotan 1, also called Melanotan I or afamelanotide, is a synthetic peptide that imitates a natural signal involved in skin pigmentation. It encourages pigment-producing cells to make more eumelanin, the brown-black pigment in skin. Think of it as a message to the skin’s pigment workshop asking it to increase production. A prescription implant containing afamelanotide has a specific medical use in a rare light-sensitivity disorder; this is different from assuming that every product sold as MT-1 is equivalent.
SOURCE REFERENCE
Mixing and dose chart
Current aggregated data suggests the following information:
Each row shows a separate source example for Melanotan I.
Bacteriostatic water is a source assumption. Amounts and schedules are not independently verified or personal medical advice. Consult a qualified clinician.
Peptide per Vial (mg)
BAC water
U-100 syringe
Frequency
10 mg
2 mL
10 UNITS
2 times per week for 8 weeks, followed by an 8-week off period.
10 mg
3 mL
15 UNITS
2 times per week for 8 weeks, followed by an 8-week off period.
THE DOSING REFERENCE
Dosing instructions
Amounts, schedules, and preparation - organized and summarized from current aggregated data
The FDA-approved afamelanotide implant, Scenesse, is indicated to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria (EPP). This indication concerns a defined disorder and formulation, rather than general cosmetic tanning or prevention of skin cancer. Evidence for the implant does not establish the identity, delivery characteristics or safety of research-vial products labeled MT-1. [49]
Mechanism, evidence and interpretation
Afamelanotide is a 13-amino-acid analogue of alpha--stimulating hormone (α-MSH), also known as [Nle4,D-Phe7]-α-MSH. It activates 1 (MC1-R), increasing eumelanin production independently of sunlight or artificial UV exposure. MT-1 and are distinct molecules, so their pharmacology and clinical evidence should be evaluated separately. [49, 50]
Source mass amounts and schedules are retained. Reviewed syringe conversions use the stated preparation; unresolved conversions are labeled unavailable. Not personal medical advice. Consult a qualified clinician for decisions about personal use.
The FDA-approved afamelanotide implant, Scenesse, is indicated to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria (EPP). This indication concerns a defined disorder and , rather than general cosmetic tanning or prevention of skin cancer. Evidence for the implant does not establish the identity, delivery characteristics or safety of research-vial products labeled MT-1. [49]
Research interpretation should distinguish increased pigmentation from clinically measured light tolerance. Relevant variables include , exposure, underlying disease and adverse effects. The prescribing information describes pigmentary changes, including darkening of existing moles and freckles, and recommends twice-yearly full-body skin examinations; patients should maintain sun and light protection measures. [49]
Melanotan I and afamelanotide
MT-1 means Melanotan I, a development name associated with afamelanotide. It is a synthetic of alpha--stimulating hormone. The molecule is different from Melanotan II, which has a shorter cyclic structure, and from PT-141, a related but distinct compound with another approved clinical use. Similar names should not obscure these chemical differences.
Afamelanotide is the active ingredient in Scenesse, a regulated implant product. The clinical evidence and prescribing information concern that preparation and a defined disease setting. A vial labeled MT-1 is not automatically equivalent to the implant. Manufacturing, and delivery influence exposure, so the active-ingredient name alone cannot transfer all of the product's instructions or approval to another preparation.
Afamelanotide acts through -related pigment signaling, particularly the MC1 pathway. It promotes production of eumelanin, a form of skin pigment. This provides a biological explanation for its investigation in light-related conditions. However, a pigment response is not the same as a demonstration that a product prevents skin cancer or makes unrestricted ultraviolet exposure safe.
Erythropoietic protoporphyria, often shortened to EPP, is a rare disorder in which accumulated protoporphyrin contributes to severe reactions to light. The treatment question concerns improving tolerance of light in people with that condition. It differs from a cosmetic tanning goal in someone without EPP. The disease mechanism, patient population and outcome being measured are therefore essential parts of interpreting the drug's action.
Randomized trials compared afamelanotide implants with in people with EPP. Investigators measured outcomes including pain-free light exposure and aspects of the disease's burden. These trials provide clinical evidence for a specific product in a specific condition. They do not evaluate a self-prepared MT-1 injection used for tanning, and they do not establish that a different delivery schedule produces the same result.
The Scenesse label describes an adult EPP indication and product-specific administration. It also discusses pigment changes and skin monitoring. Those details matter because the same pathway responsible for a desired pigment response can change the appearance of skin or existing lesions. The approved treatment remains a supervised disease-specific use, rather than a general endorsement of all pigment-enhancing preparations. Readers should check the current label when interpreting the regulated product. The implant also has a defined delivery pattern. That pattern contributes to the exposure studied in patients and should not be replaced mentally with the peak after a different injection. Matching the molecule is only one part of matching the treatment.
A historical Melanotan I study, a modern afamelanotide implant and a research vial can share a related molecular description while differing in and clinical context. The useful comparison identifies exactly which preparation was tested. It should not treat an implant's release pattern as equivalent to an occasional injection, or a rare-disease endpoint as equivalent to healthy cosmetic use.
The clearest account is that afamelanotide influences pigment signaling and has demonstrated usefulness within the labeled EPP treatment setting. Wider claims require their own evidence. Compare Melanotan II for broader -related research and PT-141 for a different -related indication. The source record above preserves historical content, while this article explains why a research schedule should not inherit an approved product's status. A darker appearance alone does not answer questions about long-term skin health, exposure risk or clinical suitability. Those questions remain specific to the preparation, person and purpose.
Melanocortin signaling and skin pigment
Skin pigment is produced by , specialized cells that make . The pigment is packaged and transferred to surrounding skin cells. signals help regulate this process through , including . A compound that activates a pigment-related receptor can change pigmentation, but the response depends on the molecule, the person's biology and the setting. A darker appearance is not a complete measurement of protection from ultraviolet exposure or of overall skin health.
The family includes several in different tissues. Some are involved in pigmentation, while others participate in appetite, energy regulation or sexual responses. A compound that activates multiple receptors can therefore have effects beyond skin color. This helps explain why Melanotan II and PT-141 are discussed in overlapping biological contexts even though their intended uses differ. Receptor activity should be described precisely rather than summarized as one general tanning or libido effect.
An approved product also needs to be distinguished from a similarly named research vial. Its , manufacturing standards, delivery method and labeled use are part of the evidence. A supervised implant studied in people with a rare light-sensitive disease is not equivalent to a self-prepared injection used for cosmetic tanning. The same broad chemical family does not remove those differences, and changing the route can change both exposure and risk.
Pigment changes require context when interpreting research. Investigators can measure , changes in existing moles or the amount of pain-free light exposure in a particular disease. Those endpoints answer different questions. A trial demonstrating a benefit for one disorder does not establish prevention of skin cancer or safety of deliberate sun exposure. The response also needs follow-up, because an immediate change in color does not describe longer-term consequences. A useful compound profile separates biology, demonstrated clinical outcomes, product identity and unresolved effects. That approach is more informative than assuming all -related products produce the same result.
How to read the research and dosing record
The dosing record above and this article serve different purposes. The record preserves source amounts and schedules. The article explains identity, biology and evidence. An archived schedule is not a clinically validated prescription, and a calculation cannot decide whether a compound is suitable for a person. Keep the exact molecule, , route and strength attached to any research claim. Do not treat an animal experiment as a human dosing instruction or transfer a prescription product's instructions to a different vial.
When checking a paper, first identify who or what was studied. Then check the comparison group, the measured outcome, the length of follow-up and reported adverse effects. A laboratory marker and a patient benefit are different endpoints. Small exploratory studies can help generate a hypothesis, while larger controlled studies can test it more reliably. Internal compound links provide comparisons, and the dotted terms open short definitions with links to the site's glossary. The source links below let you check the original context rather than relying on a headline.
Key facts
SOURCE DATA
Molecular formula
—
Molecular weight
—
CAS number
—
Sequence
—
Half-life
Not established for a general human-use regimen in the reviewed evidence.
Calculated doses are derived from the source UNITS and assume added liquid equals final volume. U-100 UNITS measure volume, not drug activity. Source UNITS may be rounded or differ from an explicit dose; see the detailed source protocol below.
Source reference for research and education. Not personal medical advice. Amounts and clinical suitability are not independently verified. Conversion checks are labeled below.
Source review note
Source-reported quantities and schedules are educational comparisons, not verified administration instructions. Route, diluent compatibility, vial capacity, final volume and clinical suitability are unverified. Added liquid is assumed to equal final volume only for arithmetic. U-100 UNITS measure volume; drug activity IU is a separate unit.
Source review note
Source-reported quantities and schedules are educational comparisons, not verified administration instructions. Route, diluent compatibility, vial capacity, final volume and clinical suitability are unverified. Added liquid is assumed to equal final volume only for arithmetic. U-100 UNITS measure volume; drug activity IU is a separate unit.
Source-specific review note
Schedule and syringe quantities are source-reported research-vial examples. Preparation, product identity and suitability are unverified. The evidence for the approved afamelanotide implant applies to that formulation.
Source-specific review note
Schedule and syringe quantities are source-reported research-vial examples. Preparation, product identity and suitability are unverified. The evidence for the approved afamelanotide implant applies to that formulation.
Research discussion 0
Share a source, ask a question, or add context. Every comment is reviewed before it appears publicly.
Explore the peptide forum → for dedicated threads and nested conversations.
Save your research and join the conversation.
Sign in to comment